DRESS-1
Duodenal Recellularization Via Electroporation Therapy for Suboptimally Controlled Type II Diabetes Mellitus and Steatotic Liver Disease (DRESS-1 Study)
Sponsor study identifier
interventional
40
1 country
1
Study Start
September 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
August 30, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
August 30, 2033
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This study is designed to evaluate the efficacy, safety, and mechanisms of pulsENDO procedure in patients with T2DM and its effect on MASLD.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 30, 2033
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 28, 2026
Actual (reported)February 5, 2026
Actual (reported)September 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
August 30, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
August 30, 2033
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
HbA1c
Change in HbA1c (%) from baseline to Month 24
24 months post-procedure
Improvement of MAFLD
Proportion of subjects with improvement of liver steatosis and without worsening of fibrosis on liver histology
12 months post-procedure
Total body weight loss (%TBWL)
24 months post-procedure
Incidence of adverse events
within 30 days post-procedure
Body fat percentage
24 months post-procedure
Change in Quality of Life
24 months post-procedure
Faecal microbiome
24 months post-procedure
pulsENDO procedure entails the ablation of the duodenal mucosa with irreversible electroporation (IRE)
The pulsENDO procedure utilizes the pulsENDO catheter to deliver non-thermal pulsed electric field to the duodenum to induce cell regeneration. The catheter is introduced to the duodenum through the mouth using a guide wire and the therapy is applied to treat the duodenum under endoscopic visualisation, starting from D4 and repeated proximally. Approximately 10-18 cm of axial length of the duodenum is treated.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Chinese University of Hong Kong
Shatin, Hong Kong
Stephen Ng, FRCSEd(Gen)
Prince of Wales Hospital, the Chinese University of Hong Kong
First Submitted
January 28, 2026
First Posted
February 5, 2026
Study Start
September 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
August 30, 2031
Anti-inflammatory Dietary Intervention in Patients With Type 2 Diabetes: A Randomized Controlled Trial
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
August 30, 2033
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
September 15, 2026
Record last verified: 2026-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: